NAD+ is the most aggressively marketed molecule in the longevity space, which is exactly why it deserves the most careful physician read. The mitochondrial biology is real. The precursor randomized trials (nicotinamide riboside, NMN) are real but report narrow endpoints. The IV and subcutaneous clinical-endpoint trials are early. Most of what you see on Instagram about "300 mg of NAD+ reversing aging" is — to put it plainly — not in the literature.
NAD+ is still on my personal protocol recommendation for nearly every adult patient at Limitless. This article explains why that is consistent with the evidence as it stands in May 2026, and why the marketing claims are not.
The biology, in one paragraph.
Nicotinamide adenine dinucleotide is a coenzyme present in every cell. It is the substrate that powers electron transport in the mitochondria (NAD+/NADH cycling), the substrate sirtuins use to deacetylate histones and metabolic enzymes (SIRT1–SIRT7), and the substrate PARPs consume during DNA-damage repair. Tissue NAD+ falls measurably with age in skeletal muscle, liver, and skin — confirmed in human biopsy data, not just animal models. Restoring NAD+ does not "reverse aging." It restores a coenzyme pool that age and metabolic disease deplete. Those are different claims.
Three tiers of NAD+ evidence.
Patients deserve to know which tier any given recommendation rests on. Mine, here, do too.
| Intervention | Evidence tier | Limitless posture |
|---|---|---|
| Oral nicotinamide riboside (NR) | Multiple human RCTs. Raises whole-blood NAD+ 40–90%. Generally well tolerated. Clinical endpoints (BP, inflammation, muscle function) modest and variable. | Reasonable adjunct for patients who prefer oral. Not the most efficient route for tissue restoration. |
| Oral nicotinamide mononucleotide (NMN) | Several small RCTs (Yoshino, Igarashi, Pencina, Liao). Aerobic capacity, insulin sensitivity, and walking-distance signals at 250–900 mg. FDA's NDI-disqualification posture is regulatory, not safety-based. | Reasonable adjunct for patients seeking oral support. Quality and sourcing matter — we vet brands. |
| IV NAD+ (loading) | Pharmacokinetic data (Grant 2019, Conlon 2021) confirms acute plasma rise. Clinical endpoint trials limited but growing — substance-use disorder pilots, fatigue/long-COVID open-label series. | 5-infusion loading protocol (750 mg each, over 2 weeks) when the patient and presentation justify it. Honest informed consent about the endpoint evidence. |
| Subcutaneous NAD+ (maintenance) | Pharmacokinetic advantage — sustained plasma exposure without 2-hour IV chair time. Clinical-endpoint data is early but consistent with the precursor and IV literature. | 100–200 mg SubQ daily or every other day after the IV load. Lower-burden maintenance for engaged patients. |
| NAD+ "skin patches" / "nasal sprays" | Marketing has outrun the pharmacokinetic data. Most products do not document plasma delivery. | Not on the Limitless menu. Not recommended. |
What the precursor RCTs show.
Nicotinamide riboside has been studied in placebo-controlled human trials at 250–1000 mg/day for durations of 6 to 21 weeks. Whole-blood NAD+ rises reliably and dose-dependently. Systolic blood pressure modestly declines in adults with elevated baseline. Markers of inflammation (IL-6, hsCRP) trend down in some cohorts. Muscle function and exercise endpoints are mixed — Dolopikou (2020) showed sprint performance gains; Elhassan (2019) showed metabolic adaptations without functional gains. The takeaway is that oral NR raises NAD+ but produces relatively modest clinical effects on its own. It is a supplement, not a transformative intervention.
NMN trials have shown similar NAD+ elevation plus a small but consistent signal on aerobic capacity (Liao 2021, walking distance and VO2 in older adults) and on insulin sensitivity in prediabetic women (Yoshino 2021). The endpoints are not enormous. They are real.
Why IV and SubQ NAD+ are not the same as oral.
Oral NAD+ itself is not bioavailable — it is broken down before absorption. Oral therapy works through precursors (NR, NMN, niacinamide) that the body then assembles into NAD+. IV and SubQ NAD+ bypass that conversion step and deliver the molecule directly. The Grant 2019 pharmacokinetic study and the Conlon 2021 follow-up both demonstrate that infused NAD+ produces an acute plasma rise that oral precursors cannot match. Subcutaneous NAD+ — administered the same way patients are now familiar with from peptide injections — extends that delivery into a less burdensome maintenance pattern.
This is the mechanism behind the Limitless loading-plus-maintenance protocol: five IV infusions of 750 mg over two weeks to saturate tissue stores, then 100–200 mg SubQ daily or every other day to maintain the elevation. The pharmacokinetics argue for it. The clinical-endpoint evidence is still maturing.
What the skeptics get right.
Three things, all worth conceding. First, the longevity-endpoint trials in humans simply do not exist. Anyone claiming NAD+ extends lifespan in people is overshooting the data — the mouse Brenner and Auwerx lifespan signals are real, but they are mouse signals. Second, oral NMN's regulatory status in the United States is unsettled; the FDA has taken the position that NMN is not a permitted dietary-supplement ingredient under the NDI framework. That is a regulatory posture, not a safety finding, but it matters for sourcing. Third, "feel-better" testimonials are not endpoints. Patients reporting more energy on NAD+ may be experiencing a real effect, a placebo effect, or both. The honest physician does not pretend to know which.
What the skeptics understate.
The mitochondrial and sirtuin biology is robust across organisms and tissues. Tissue NAD+ decline with age is replicated in human muscle biopsy. The precursor RCTs do raise NAD+ and do move metabolic markers in the expected direction. The IV pharmacokinetic data is unambiguous. Calling the entire NAD+ category "hype" because the lifespan trial has not been run is a different kind of overshooting. The right reading is that this is a mature biology with maturing clinical data, not a new fad.
The Limitless rules for NAD+.
- Indication-anchored, not "vibe-based." Energy decline with metabolic markers, recovery demand, neuroinflammation, addiction-recovery support, or a patient explicitly pursuing longevity protocols under informed consent.
- 503A pharmacy sourcing only. IV and SubQ NAD+ is compounded; we vet our pharmacy partners on USP 797/795 compliance and COA reporting.
- Loading + maintenance, not one-off. One IV infusion will not move tissue NAD+ meaningfully. The 5×750 mg load is the dose the pharmacokinetic data supports.
- Honest informed consent. The patient hears the evidence tier before the prescription. "Coenzyme restoration with maturing endpoint data," not "anti-aging breakthrough."
- Hard exclusions. Active malignancy (theoretical PARP/sirtuin substrate-competition concerns), pregnancy, and uncontrolled metabolic instability are absolute. Documented in the chart.
- No retail "NAD patches" or "nasal NAD." The pharmacokinetic data does not support these.
What we don't claim.
We do not claim NAD+ extends lifespan. We do not claim it reverses aging. We do not claim a specific cognitive, performance, or longevity endpoint that the human trials have not measured. We do claim that restoring a depleted coenzyme pool is a mechanistically sound, well-tolerated intervention with a maturing evidence base — and that for the patient who values that profile under transparent informed consent, the Limitless loading-plus-maintenance protocol is a defensible offering.
The bottom line.
NAD+ is not the fountain of youth. It is also not snake oil. It is a coenzyme that age and disease deplete, that supplementation can restore, that mitochondrial and sirtuin biology depends on, and that — administered through routes the pharmacokinetic data supports — gives patients an evidence-based way to participate in their own metabolic maintenance. That is the honest case. It is the only case Limitless makes.